Literature DB >> 18046334

The interplay between MYC and HIF in cancer.

Chi V Dang1, Jung-whan Kim, Ping Gao, Jason Yustein.   

Abstract

The interaction of MYC and hypoxia inducible factors (HIFs) under physiological, non-tumorigenic conditions provides insights into normal homeostatic cellular responses to low oxygen levels (hypoxia). Many tumours contain genetic alterations, such as MYC activation, that can collaborate with HIF to confer metabolic advantages to tumour cells, which tend to exist in a hypoxic microenvironment. This Perspective emphasizes the differences between the transcriptional network that operates under normal homeostatic conditions and the network in a tumorigenic milieu.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18046334     DOI: 10.1038/nrc2274

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  255 in total

Review 1.  Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA.

Authors:  Mo Chen; Jian Zhang; James L Manley
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

2.  The HIF-1α-c-Myc pathway and tumorigenesis: evading the apoptotic gate-keeper.

Authors:  Nicole Fer; Giovanni Melillo
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

3.  FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis.

Authors:  Boyi Gan; Carol Lim; Gerald Chu; Sujun Hua; Zhihu Ding; Michael Collins; Jian Hu; Shan Jiang; Eliot Fletcher-Sananikone; Li Zhuang; Michelle Chang; Hongwu Zheng; Y Alan Wang; David J Kwiatkowski; William G Kaelin; Sabina Signoretti; Ronald A DePinho
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

Review 4.  MYC, Metabolism, and Cancer.

Authors:  Zachary E Stine; Zandra E Walton; Brian J Altman; Annie L Hsieh; Chi V Dang
Journal:  Cancer Discov       Date:  2015-09-17       Impact factor: 39.397

5.  Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.

Authors:  Javier A Menendez; Tomás Alarcón; Jorge Joven
Journal:  Cell Cycle       Date:  2014-02-03       Impact factor: 4.534

Review 6.  Beyond Alkylating Agents for Gliomas: Quo Vadimus?

Authors:  Vinay K Puduvalli; Rekha Chaudhary; Samuel G McClugage; James Markert
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

7.  Hepatic glucose-6-phosphatase-α deficiency leads to metabolic reprogramming in glycogen storage disease type Ia.

Authors:  Jun-Ho Cho; Goo-Young Kim; Brian C Mansfield; Janice Y Chou
Journal:  Biochem Biophys Res Commun       Date:  2018-03-14       Impact factor: 3.575

8.  Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model.

Authors:  Jessica A Bertout; Shetal A Patel; Benjamin H Fryer; Amy C Durham; Kelly L Covello; Kenneth P Olive; Michael H Goldschmidt; M Celeste Simon
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

9.  Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1).

Authors:  Markus Hartl; Andrea Nist; M Imran Khan; Taras Valovka; Klaus Bister
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

10.  Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review).

Authors:  Jie Zheng
Journal:  Oncol Lett       Date:  2012-09-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.